Updates in the Treatment of DLBCL – From Chemotherapy to Novel Targeted Therapies

 
Release Date: November 12, 2021
Expiration Date: November 11, 2022

Overview
Podium to Practice is an accredited continuing education activity featuring two renowned experts who are actively engaged in clinical trials and the management of patients with diffuse large B-cell lymphoma (DLBCL). 

Target Audience
This target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat DLBCL patients.

Learning Objectives
After participating in this activity, learners should be better able to:

• Compare and contrast various chemotherapy treatment regimens for the frontline treatment of patients with DLBCL
• Assess the safety and efficacy of clinical data regarding novel targeted therapeutic approaches for patients with relapsed/refractory DLBCL
• Identify strategies for improving patient outcomes, including optimal selection and sequencing of therapy, as well as adverse event management approaches

Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend.  University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in and receiving continuing education credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive an accredited continuing education credit certificate.

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Justin Kline, MD (Moderator)
Director, Lymphoma Program
Associate Professor of Medicine
University of Chicago Medicine
Chicago, Illinois

Consultant Fees: Merck, Verastem, MorphoSys, Gilead, Karyopharm
Research Support: Merck, Verastem
Speakers Bureau: Kite/Gilead

Laurie Sehn, MD
Clinical Assistant Professor, Division of Medical Oncology
The University of British Columbia
Vancouver, British Columbia

Consultant Fees: Abbvie, AstraZeneca, Celgene, Gilead/Kite, Incyte, Janssen, Merck, Roche Genentech, Teva, Sandoz, Seattle Genetics

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Chloe Dunnam; Dru Dace, PhD; Kraig Steubing

Support
Educational grant support provided by Merck Sharp & Dohme Corp and Genentech, Inc.

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.